NASDAQ: KARDKardigan Inc Stock
$16.64-0.05 (-0.3%)
Updated Sep 18, 2026
KARD Price
$16.64
Fair Value Price
$1.59
Market Cap
$1.56B
52 Week Low
$15.86
52 Week High
$27.00
P/E
N/A
P/B
2.53x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.17
Operating Cash Flow
N/A
Beta
1.91
Next Earnings
Nov 10, 2026
Ex-Dividend
N/A
Next Dividend
N/A
KARD Overview
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine KARD's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
KARD
Ranked#282 of 461
Ranked#282 of 461
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.60 | A | |
| $350.84 | A | |
| $42.02 | A |
Be the first to know about important KARD news, forecast changes, insider trades & much more!
KARD News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KARD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KARD ($16.64) is overvalued by 948.43% relative to our estimate of its Fair Value price of $1.59 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
KARD ($16.64) is not significantly undervalued (948.43%) relative to our estimate of its Fair Value price of $1.59 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
KARD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more KARD due diligence checks available for Premium users.
Valuation
KARD fair value
Fair Value of KARD stock based on Discounted Cash Flow (DCF)
Price
$16.64
Fair Value
$1.59
Overvalued by
948.43%
KARD ($16.64) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KARD ($16.64) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KARD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.53x
Industry
5.28x
KARD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KARD's financial health
Profit margin
Revenue
$0.0
Net Income
-$116.2M
Profit Margin
0%
Assets to liabilities
Assets
$721.8M
Liabilities
$106.3M
Debt to equity
0.17
KARD's short-term assets ($610.16M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KARD's short-term assets ($610.16M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KARD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$50.6M
Investing
-$73.9M
Financing
$426.9M
KARD vs Biotech Stocks
Kardigan Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.